News
Displaying 331–340 of 508
-
ARVO 2019 Highlight: RP Patients in ReNeuron’s Cell Therapy Trial Show Further Vision Improvements
Research NewsThe latest ReNeuron results were presented at the sixth annual Retinal Cell and Gene Therapy Innovation Summit held on April 26 in Vancouver, Canada.
-
First Patient Receives AON Therapy for LCA10 in ProQR’s Phase 2/3 Clinical Trial
Research NewsThe treatment, formerly known as QR-110, is designed for people with the retinal disease Leber congenital amaurosis 10
-
Foundation Fighting Blindness Announces Staffing Changes to Enhance Strategic Direction
Foundation NewsThe Foundation announces several staffing changes with a focus on new strategies to increase awareness and engagement with the community.
-
First Gene Therapy for Dry AMD Moves into Clinical Trial in UK
Research NewsGyroscope Therapeutics, a gene-therapy development company in the UK, has launched the first gene therapy clinical trial for the dry form of age-related macular degeneration (AMD).
-
First Patient Receives ProQR’s Emerging USH2A Therapy in Clinical Trial
Research NewsProQR, a developer of RNA therapies in the Netherlands, announced that the first clinical-trial participant has received its emerging treatment, which targets retinitis pigmentosa and Usher syndrome caused by mutations in exon 13 of the USH2A gene.
-
The Foundation Fighting Blindness and Dr. H. James & Carole Free Collaborate to Combat AMD
Foundation NewsAge-related macular degeneration (AMD) is the leading cause of blindness for people over 50 years of age in developed countries.
-
Encouraging Vision Improvements Reported in ReNeuron's Cell-Therapy Clinical Trial
Research NewsReNeuron, a cellular therapy developer in the UK, has reported vision improvements in the treated eyes of the first three retinitis pigmentosa (RP) patients in the Phase II part of the Phase I/II clinical trial for its proprietary human retinal progenitor cells (hRPC). The Phase I portion of the trial, completed last year, primarily assessed safety in subjects with minimal remaining vision.
-
The Foundation Receives a $100,000 Research Grant from Sofia Sees Hope
Research NewsSofia Sees Hope, a nonprofit dedicated to finding treatments and cures for people with Leber congenital amaurosis (LCA) and other inherited retinal diseases (IRDs), has made a $100,000 donation to the Foundation Fighting Blindness to support therapy development and genetic testing.
-
Pixium's PRIMA Bionic Vision System Restores Central Vision in Dry AMD Clinical Trial
Research NewsThe French bioelectronics company Pixium Vision has reported that its PRIMA bionic vision system has restored some central vision in patients with advanced dry age-related macular degeneration (AMD) participating in a clinical feasibility trial.
-
Research News
Applied Genetic Technologies Corporation (AGTC), a leading developer of gene therapies, has reported the six-month follow-up data in all patients treated with its gene therapy for X-linked retinoschisis (XLRS) in its Phase I/II clinical trial.
